Germany · Delayed Price · Currency is EUR Sensorion Company Description
Sensorion SA, a biotechnology company, develops drug candidates for the treatment of inner ear disorders in France.
The company’s product portfolio includes SENS-401 SSNHL, which has completed Phase 2b clinical trial for the treatment of Sudden Sensorineural Hearing Loss; SENS-401 CIO that is in Phase 2a clinical trial for the treatment of Cisplatin-Induced Ototoxicity; and SENS-401 Cochlear, which is in Phase 2a clinical which is an orally available small molecule protecting and preserving inner ear tissue from damage, responsible for hearing impairment.
It is also developing OTOF-GT (SENS-501), a gene therapy development program that has completed Phase 1/2 clinical trial to restore hearing in people living with Otoferlin deficiency; and GJB2-GT, a gene therapy development program, which is in pre-clinical trial to restore hearing in people living with hearing loss due to mutations in the GJB2 gene.
The company was incorporated in 2009 and is headquartered in Montpellier, France.
| Country | France |
| Founded | 2009 |
| Industry | Pharmaceutical Preparations |
| Employees | 63 |
| CEO | Nawal Ouzren |
Contact Details
Address: 375, rue du Professeur Joseph Blayac Montpellier, 34080 France | |
| Phone | 33 4 67 20 77 30 |
| Website | sensorion.com |
Stock Details
| Ticker Symbol | RFM |
| Exchange | Frankfurt Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Nawal Ouzren | Chief Executive Officer |
| Laurene Danon | Chief Financial Officer |